Recommendations Announced in Conclusion of DUPHAT 2019

Dubai, United Arab Emirates, 28 February, 2019: Under the patronage of His Highness Sheikh Hamdan bin Rashid Al Maktoum, Deputy Ruler of Dubai, Minister of Finance and President of Dubai Health Authority, the 24th edition of Dubai International Pharmaceutical and Technology Conference and Exhibition – DUPHAT today successfully concluded at the Dubai International Convention and Exhibition Center (DICEC). The 3-day premier pharma event featured a number of key scientific sessions, workshops and highly specialized sessions focusing on the latest advances taking place in the drug manufacturing industry as well as the laws and regulations governing the administration and efficacy of drugs in the region. On the third and final day, the scientific committee had released the following DUPHAT Conference recommendations:

  1. Overcoming the challenges related to the patient’s safety due to shortages in medicines is one of the major and persistent challenges that face the healthcare sector. Therefore, Pharmacists in the health system shall adopt effective and sustainable methodologies to manage the shortage of medicines in hospitals and health centers and to balance the problems of drug supply and patient safety.
  2. The role of pharmacists and pharmaceutical practice is more highlighted in the infection control team as the frequency and severity of infection risks are increasing in healthcare institutions. There is a great need for the development of new antibiotics that work within different and novel mechanisms to treat diseases caused by multidrug-resistant microbes.
  3. The modern concepts of drug-control therapy with all its components are among the most important modern strategies to treat tumors and ensure the sustainability of therapeutic outcomes. Individual pharmacotherapy is also one of the most important strategies used to ensure effective treatment. However, it should not be limited to the choice of medication, as this goes beyond the careful consideration of the dosage.
  4. Pharmacists play vital role in the direct care of the patients, as the increasing use of drugs produced through biotechnology has a significant impact on the cost of healthcare, therefore, we must find new solutions by involving the pharmacists in deciding the appropriate treatment for the patients.
  5. We shall focus on the need to develop the skills of those working in the pharmaceutical education and train them to adopt the foundations of institutional culture and apply their strategies within academic tracks to ensure a more productive environment in the future. We shall also consider new teaching methodologies to enhance the ability of pharmacists to perform their clinical roles, provide patient-focused pharmaceutical care, engage the medical team in clinical practice and play roles beyond traditional forms of pharmaceutical services.
  6. The professional infrastructure shall be adopted by updating certificates to evaluate the actual development of pharmacists, enhance their professional abilities, improve the pharmaceutical practice, and to promote research work and study of the possible medical and economic implications of new treatments, including genetic modification, gene the rapy, genetically modified cellular therapy and the new technologies affecting clinical treatment today and in the near future.
  7. Adopting clinical governance concepts to balance the delivery of high-quality integrated services while monitoring, at the same time, the financial and technical indicators of pharmaceutical practices within the framework of accountability and optimal use of financial, human and technical resources.
  8. Ensuring that the quality assurance control procedures conforms with the international standards as well as investing the technology in developing the effectiveness of quality assurance processes.
  9. Regulatory authorities shall work hand in hand with the manufacturers, distributors, wholesalers, consumer organizations and intergovernmental bodies with the assistance of technology experts to secure the supply chain track and ensure the provision of safe medicines to all patients.

This year, DUPHAT attracted over 27,500 visitors and participants from 75 countries and witnessed the attendance of 130 speakers. In addition, the conference featured 143 scientific lectures, 700 poster presentations and 22 workshops including a key workshop on ‘Pharmacists Role in the Year of Tolerance in the UAE. While the conference featured high quality discussions on a number of topics including future of pharmacy practice, quality and safety of medicines as well as skill training and education for pharmacists, DUPHAT Tech exhibition, witnessed the presence of 659 leading drug manufacturing and technology brands from the global pharmaceutical industry.

DUPHAT is organized annually by INDEX Conferences and Exhibitions – a member of INDEX Holding in strategic partnership with General Directorate of Residency and Foreigners Affairs (GDRFA) Dubai and is supported by Dubai Health Authority, International Society for Pharmacoepidemiology, European Society of Oncology Pharmacy, European Federation for Pharmaceutical science, European society of Clinical pharmacy.

Related posts